DBV Technologies: Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
Date | Total number of shares | Total number of voting rights |
| 11/30/2024 | 102,847,501 | Total gross of voting rights: 102,847,501 |
Total net* of voting rights: 102,582,335 |
* Net total = total number of voting rights attached to shares – shares without voting rights
| Last Trade: | US$8.73 |
| Daily Change: | 0.17 1.99 |
| Daily Volume: | 26,261 |
| Market Cap: | US$179.140M |
January 08, 2025 December 11, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
